The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
23 hours ago
0
0
Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue ...
Apr 13, 2024
0
1
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal ...
Apr 8, 2024
0
0
A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of the Journal of Nuclear Medicine. Combining the highly specific huAR9.6 ...
Apr 3, 2024
0
2
An estimated 2.2 million people suffer from lung cancer worldwide, making it the second most common type of cancer. Though improvements in treatment have been made, the overall survival rate of lung cancer patients is low, ...
Mar 27, 2024
0
3
A study published in the journal Science Bulletin was led by Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Chinese Thoracic Oncology Group (CTONG)).
Mar 5, 2024
0
0
A new research paper titled "Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas" has been published in ...
Mar 4, 2024
0
0
CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been shown to significantly enhance standard chemotherapy and provides clinical benefits for the patients ...
Feb 22, 2024
0
0
A newly identified genetic marker could potentially predict which patients are likely to respond to immunotherapy in cancer types that have lacked such tools until now, according to a new study published in Cancer Immunology ...
Feb 13, 2024
0
39
A phase III LIBRETTO-431 multicenter study has evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune ...
Jan 5, 2024
0
1
